Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the ...
MM&M6 小时
Takeda takes stab at CTV rare disease marketing with HyQvia campaign
Takeda is rolling out its first rare disease CTV campaign for its chronic inflammatory demyelinating polyneuropathy (CIDP) ...
Monthly Prescribing Reference11 小时
Ustekinumab Biosimilar Steqeyma Gets FDA Approval
The Food and Drug Administration (FDA) has approved Steqeyma ® (ustekinumab-stba), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases in adults and ...
healthday3 小时
FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitis
The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-sev ...
infectiousdiseaseadvisor.com12 小时
Tobevibart Plus Elebsiran Designated Breakthrough Therapy for Chronic Hepatitis Delta
The FDA has granted Breakthrough Therapy designation to the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta in adults.